Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C
[at noodls] – — If Approved, Fixed-Dose Combination Would be First Oral Treatment Regimen for Patients with Genotype 1 HCV Infection, Eliminating Need for Both Interferon and Ribavirin — FOSTER CITY, Calif.–(BUSINESS … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]